Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020)
Abstract Our study assessed DATASUS as a potential source for pharmacoepidemiologic studies in rheumatoid arthritis (RA) in the Brazilian population focusing on treatment patterns and determinants of initiating or switching to a novel therapy. This was a descriptive database study of RA patients wit...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-44389-9 |
| _version_ | 1797453003613011968 |
|---|---|
| author | Marina G. Birck Rafaela Ferreira M. Curi Whitney S. Krueger Guilherme S. Julian Alexander Liede |
| author_facet | Marina G. Birck Rafaela Ferreira M. Curi Whitney S. Krueger Guilherme S. Julian Alexander Liede |
| author_sort | Marina G. Birck |
| collection | DOAJ |
| description | Abstract Our study assessed DATASUS as a potential source for pharmacoepidemiologic studies in rheumatoid arthritis (RA) in the Brazilian population focusing on treatment patterns and determinants of initiating or switching to a novel therapy. This was a descriptive database study of RA patients with at least one claim of RA and ≥ 2 claims of disease-modifying anti-rheumatic drug (DMARD); conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARD with more than 6 months of follow-up from 01-Jan-2010 to 31-Dec-2020. Analyses were stratified for SUS-exclusive and SUS+ private user cohorts. We identified 250,251 patients with RA in DATASUS: mean age of 58.4 years, majority female (83%) and white (58%). 62% were SUS-exclusive and 38% SUS+ private. Most common bDMARDs were adalimumab and etanercept. Age (adjusted odds ratio 1.78 [50+]; 95% CI 1.57–2.01), SUS exclusive status (0.53; 0.47–0.59), distance to clinic [160+ km] (0.57; 0.45–0.72), and pre-index csDMARD claims (1.23; 1.08–1.41) were independent predictors of initiating a novel oral tsDMARD. Switching from bDMARD to tsDMARD, associations were similar, except for the direction of associations for SUS exclusive status (adjusted hazard ratio 1.10; 1.03–1.18), distance to clinic (1.18; 1.03–1.35), and number of previous bDMARD (0.15; 0.14–0.16). DATASUS is a source suitable for treatment-related analyses in RA reflecting the public health system in Brazil. |
| first_indexed | 2024-03-09T15:16:36Z |
| format | Article |
| id | doaj.art-7587068b18d54d0e9f7dfb95a4f912d0 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-09T15:16:36Z |
| publishDate | 2023-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-7587068b18d54d0e9f7dfb95a4f912d02023-11-26T13:03:47ZengNature PortfolioScientific Reports2045-23222023-10-0113111110.1038/s41598-023-44389-9Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020)Marina G. Birck0Rafaela Ferreira1M. Curi2Whitney S. Krueger3Guilherme S. Julian4Alexander Liede5IQVIA BrasilIQVIA BrasilAbbVieAbbVie Inc.IQVIA BrasilAbbVie Inc.Abstract Our study assessed DATASUS as a potential source for pharmacoepidemiologic studies in rheumatoid arthritis (RA) in the Brazilian population focusing on treatment patterns and determinants of initiating or switching to a novel therapy. This was a descriptive database study of RA patients with at least one claim of RA and ≥ 2 claims of disease-modifying anti-rheumatic drug (DMARD); conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARD with more than 6 months of follow-up from 01-Jan-2010 to 31-Dec-2020. Analyses were stratified for SUS-exclusive and SUS+ private user cohorts. We identified 250,251 patients with RA in DATASUS: mean age of 58.4 years, majority female (83%) and white (58%). 62% were SUS-exclusive and 38% SUS+ private. Most common bDMARDs were adalimumab and etanercept. Age (adjusted odds ratio 1.78 [50+]; 95% CI 1.57–2.01), SUS exclusive status (0.53; 0.47–0.59), distance to clinic [160+ km] (0.57; 0.45–0.72), and pre-index csDMARD claims (1.23; 1.08–1.41) were independent predictors of initiating a novel oral tsDMARD. Switching from bDMARD to tsDMARD, associations were similar, except for the direction of associations for SUS exclusive status (adjusted hazard ratio 1.10; 1.03–1.18), distance to clinic (1.18; 1.03–1.35), and number of previous bDMARD (0.15; 0.14–0.16). DATASUS is a source suitable for treatment-related analyses in RA reflecting the public health system in Brazil.https://doi.org/10.1038/s41598-023-44389-9 |
| spellingShingle | Marina G. Birck Rafaela Ferreira M. Curi Whitney S. Krueger Guilherme S. Julian Alexander Liede Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) Scientific Reports |
| title | Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) |
| title_full | Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) |
| title_fullStr | Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) |
| title_full_unstemmed | Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) |
| title_short | Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) |
| title_sort | real world treatment patterns of rheumatoid arthritis in brazil analysis of datasus national administrative claims data for pharmacoepidemiology studies 2010 2020 |
| url | https://doi.org/10.1038/s41598-023-44389-9 |
| work_keys_str_mv | AT marinagbirck realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 AT rafaelaferreira realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 AT mcuri realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 AT whitneyskrueger realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 AT guilhermesjulian realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 AT alexanderliede realworldtreatmentpatternsofrheumatoidarthritisinbrazilanalysisofdatasusnationaladministrativeclaimsdataforpharmacoepidemiologystudies20102020 |